ATE67408T1 - Arzneimittel mit verzoegerter freigabe in oraler dosisform. - Google Patents

Arzneimittel mit verzoegerter freigabe in oraler dosisform.

Info

Publication number
ATE67408T1
ATE67408T1 AT87305872T AT87305872T ATE67408T1 AT E67408 T1 ATE67408 T1 AT E67408T1 AT 87305872 T AT87305872 T AT 87305872T AT 87305872 T AT87305872 T AT 87305872T AT E67408 T1 ATE67408 T1 AT E67408T1
Authority
AT
Austria
Prior art keywords
oral dosage
delayed
dosage form
release medication
matrix
Prior art date
Application number
AT87305872T
Other languages
English (en)
Inventor
Claire Jacqueline Lovegrove
Anthony John Phillips
David Alexander Rawlins
David Alexander Tainsh
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE67408T1 publication Critical patent/ATE67408T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT87305872T 1986-07-09 1987-07-02 Arzneimittel mit verzoegerter freigabe in oraler dosisform. ATE67408T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868616669A GB8616669D0 (en) 1986-07-09 1986-07-09 Pharmaceutical compositions
EP87305872A EP0253541B1 (de) 1986-07-09 1987-07-02 Arzneimittel mit verzögerter Freigabe in oraler Dosisform

Publications (1)

Publication Number Publication Date
ATE67408T1 true ATE67408T1 (de) 1991-10-15

Family

ID=10600761

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87305872T ATE67408T1 (de) 1986-07-09 1987-07-02 Arzneimittel mit verzoegerter freigabe in oraler dosisform.

Country Status (17)

Country Link
US (1) US4919938A (de)
EP (1) EP0253541B1 (de)
JP (1) JP2528130B2 (de)
KR (1) KR880001288A (de)
AT (1) ATE67408T1 (de)
AU (1) AU598280B2 (de)
CA (1) CA1303502C (de)
DE (1) DE3773070D1 (de)
DK (1) DK352387A (de)
ES (1) ES2038181T3 (de)
GB (1) GB8616669D0 (de)
GR (1) GR3002755T3 (de)
IE (1) IE59786B1 (de)
IL (1) IL83017A0 (de)
NZ (1) NZ220875A (de)
PT (1) PT85213B (de)
ZA (1) ZA874960B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786509A (en) * 1987-05-18 1988-11-22 Schering Corporation Dry sustained release theophylline oral formulation
EP0325086A3 (de) * 1987-11-23 1990-10-31 Jago Research Ag Verfahren zur Herstellung von therapeutischen Systemen mit gesteuerter Freigabe des Wirkstoffes
DE3739690A1 (de) * 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
FR2640876B1 (de) * 1988-12-28 1993-09-24 Jouveinal Sa
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5108756A (en) * 1989-01-12 1992-04-28 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US4931286A (en) * 1989-04-19 1990-06-05 Aqualon Company High gloss cellulose tablet coating
US5175003A (en) * 1990-04-06 1992-12-29 Biosytes Usa, Inc. Dual mechanism controlled release system for drug dosage forms
US5576306A (en) * 1991-03-01 1996-11-19 Dow Chemical Company Pharmaceutical compositions and uses of water-soluble, high-viscosity grade cellulose ethers
US5721221A (en) * 1991-03-08 1998-02-24 Regents Of The University Of Minnesota Lowering blood cholesterol levels using water soluble cellulose ethers
ATE183642T1 (de) * 1991-10-04 1999-09-15 Yoshitomi Pharmaceutical Tablette mit verzögerter freisetzung
EP0676967A4 (de) * 1992-12-30 1996-10-02 Fmc Corp Leicht verfügbarer hilfsstoff zur verzögerten freisetzung auf der basis von konjac glukomannan.
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
BR9713774A (pt) * 1996-12-20 2000-03-21 Reckitt & Colman France Recipiente para uma composição de cera para depilação e/ou dispositivo para utilização em conjunto com dito recipiente, aparelho para a remoção de pelos do corpo, e, processo para remover pelos do corpo
AU6310898A (en) * 1997-03-14 1998-10-12 Toray Industries, Inc. Sustained-release prostaglandin i derivative preparation
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
US6090411A (en) * 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
AU2001247887A1 (en) * 2000-04-19 2001-11-07 Eurand America Inc. Dual mechanism timed release dosage forms for low dose drugs
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
MXPA04003807A (es) * 2001-11-30 2004-07-30 Pfizer Prod Inc Formulaciones farmaceuticas de 5, 7, 14-trianzatetraciclo [10.3.1.02, 11, 04, 9]-hexadeca -2 (11), 3, 5, 7, 9-pentaeno.
AU2002357506A1 (en) * 2001-12-25 2003-07-15 Takeda Chemical Industries, Ltd. Acid-containing preparations
CA2479350A1 (en) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
TW200306866A (en) * 2002-05-07 2003-12-01 Akzo Nobel Nv A method to improve surface properties of pharmaceutical tablets
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
AU2003284942A1 (en) * 2002-10-30 2004-06-07 Pharmacia Corporation Oral extended release tablets and methods of making and using the same
JP2006515008A (ja) * 2003-01-28 2006-05-18 コレギウム ファーマシューティカル， インコーポレイテッド 経口投与のためのミルナシプランの多粒子状組成物
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
US20080020041A1 (en) * 2004-10-19 2008-01-24 Ayres James W Enteric Coated Compositions that Release Active Ingredient(s) in Gastric Fluid and Intestinal Fluid
CN100548309C (zh) * 2004-11-24 2009-10-14 东北制药总厂 司他夫定缓释片剂
EP2412366A4 (de) * 2009-03-25 2013-08-07 Lintec Corp Feste zubereitung
JP2015527372A (ja) * 2012-08-22 2015-09-17 ゼノポート，インコーポレイティド 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468172A (en) * 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
JPS5659707A (en) * 1979-10-19 1981-05-23 Toyo Jozo Co Ltd Lasting antibiotic pharmaceutical and its preparation
US4252786A (en) * 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet
JPS5770816A (en) * 1980-10-17 1982-05-01 Ono Pharmaceut Co Ltd Multilayered film preparation of prostagladin of prolonged action
CA1204745A (en) * 1981-11-20 1986-05-20 Merck Co. Hexahydronaphth (1,2-b) -1,4 -oxazines
US4420480A (en) * 1981-11-20 1983-12-13 Merck & Co., Inc. Hexahydronaphth[1,2-b]-1,4-oxazines
JPS58134019A (ja) * 1982-02-05 1983-08-10 Ono Pharmaceut Co Ltd プロスタグランジン含有持続放出型三層状フイルム製剤及びその製造方法
DK151608C (da) * 1982-08-13 1988-06-20 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat med kontrolleret afgivelse
US4505890A (en) 1983-06-30 1985-03-19 E. R. Squibb & Sons, Inc. Controlled release formulation and method
FR2556965B1 (fr) 1983-12-21 1986-08-22 Rhone Poulenc Sante Nouvelle forme galenique du ketoprofene a liberation controlee
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
HU193979B (en) * 1984-06-12 1987-12-28 Sandoz Ag Process for producing naphtoxazine derivatives and pharmaceutical compositions containing them
US4610870A (en) 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
AU592065B2 (en) * 1984-10-09 1990-01-04 Dow Chemical Company, The Sustained release dosage form based on highly plasticized cellulose ether gels
US4695591A (en) * 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4693896A (en) * 1985-10-07 1987-09-15 Fmc Corporation Ethylcellulose-coated, gastric-disintegrable aspirin tablet
US4816264A (en) * 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
IT1213080B (it) * 1986-06-17 1989-12-07 Recordati Chem Pharm Sistemi terapeutico per la cessione controllata di farmaci.

Also Published As

Publication number Publication date
ZA874960B (en) 1988-08-31
CA1303502C (en) 1992-06-16
DE3773070D1 (de) 1991-10-24
IL83017A0 (en) 1987-12-20
EP0253541A3 (en) 1988-04-27
ES2038181T3 (es) 1993-07-16
AU7534087A (en) 1988-01-14
GB8616669D0 (en) 1986-08-13
JP2528130B2 (ja) 1996-08-28
IE871830L (en) 1988-01-09
JPS6323814A (ja) 1988-02-01
GR3002755T3 (en) 1993-01-25
DK352387D0 (da) 1987-07-08
PT85213A (en) 1987-07-01
KR880001288A (ko) 1988-04-22
IE59786B1 (en) 1994-04-06
AU598280B2 (en) 1990-06-21
EP0253541A2 (de) 1988-01-20
NZ220875A (en) 1990-11-27
US4919938A (en) 1990-04-24
DK352387A (da) 1988-01-10
EP0253541B1 (de) 1991-09-18
PT85213B (pt) 1990-03-30

Similar Documents

Publication Publication Date Title
DE3773070D1 (de) Arzneimittel mit verzoegerter freigabe in oraler dosisform.
AT400295B (de) Orale feste pharmazeutische dosierungsform mit programmierter wirkstofffreisetzung und verfahren zu ihrer herstellung
DE3650657D1 (de) Pharmazeutische Formulierung mit gesteuerter Freigabe
SE8504720D0 (sv) New drug preparation
DE3773442D1 (de) Dosierungsform zur verabreichung eines medikaments mit mitteln zur regelung der loeslichkeit.
FI906344A0 (fi) Kontrollerat frigoerande farmaceutiskt preparat.
ATE71837T1 (de) Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.
ATE112678T1 (de) Einzeldosen mit verzögerter arzneistofffreigabe.
FI885460L (fi) Menetelmä suun kautta annettavaksi tarkoitetun, aktiiviyhdistettä kontrolloidusti vapauttavan farmaseuttisen formulaation valmistamiseksi
ATE64528T1 (de) Tablette zur pharmazeutischen anwendung sukzessiver freisetzung.
DE68900994D1 (de) Diphosphonsaeurederivat enthaltendes arzneimittel zur oralen gabe.
NO177177C (no) Fremgangsmåte for fremstilling av en flytende doseringsform for oral administrasjon av en farmasöytisk substans
ATE87201T1 (de) Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung.
SE8803822D0 (sv) Novel dosage form
ATE124255T1 (de) Im dickdarm zerfallende, polypeptide enthaltende orale formulierungen.
IT1153487B (it) Prodotti farmaceutici in forma-ritardo e procedimento per ottenerli
ES2043744T3 (es) Sistema de suministro transdermico de procaterol.
DE68902300D1 (de) Pharmazeutische loesung enthaltend salbutamol und cromoglycinsaeure.
NO892764D0 (no) Medikamentell administreringsform for droevtyggere.
DE3681856D1 (de) Pharmazeutische 2-oxopyrrolidinverbindungen, ihre salze und ihre herstellung.
ATE59551T1 (de) Feste orale arzneiformen mit gestaffelter wirkung zur verabreichung von wirkstoffen mit geschwuere erzeugender nebenwirkung.
DE3772965D1 (de) Imidazol-derivate mit therapeutischer aktivitaet, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.
DK101781A (da) Fremgangsmaade til fremstilling af 10/substituerede 5-cyamethylen-dibenzo (a,d) cycloheptener
JPS56139468A (en) 10-substituted-5-cyanmethylene-10,11-dihydro- dibenzo(a,d)cycloheptene, manufacture and medicine containing same
ATA26286A (de) Verfahren zur herstellung einer pharmazeutischen zusammensetzung zur oralen verabreichung mit kontrollierter wirkstoffreisetzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee